Código QR (código de barras bidimensional)

Baricitinib and primary biliary cholangitis

Background and aims: There is an unmet need for alternative treatments for patients with primary biliary cholangitis (PBC) who do not respond to treatment with ursodeoxycholic acid (UDCA). A proof-of-concept study of baricitinib, an orally administered Janus kinase 1 and 2 inhibitor, was initiated t...

תיאור מלא

שמור ב:
Principais autores: Stuart C. Gordon, Sheri Trudeau, Arie Regev, Jonathan M. Uhas, Sujatro Chakladar, Ana Pinto-Correia, Klaus Gottlieb, Doug Schlichting
פורמט: Artigo
שפה:Inglês
יצא לאור: Elsevier 2021-01-01
סדרה:Journal of Translational Autoimmunity
נושאים:
Liver disease
Jak1/2 inhibitors
Itch
12-Week
גישה מקוונת:http://www.sciencedirect.com/science/article/pii/S2589909021000277
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים